Stoke Therapeutics, Inc. (NASDAQ: STOK) trades at approximately $32.29 per share. The genetic medicines biotechnology company operates within a 52-week trading range anchored by a lower boundary of roughly $18.20 and an upper peak of $40.22, supported by a market capitalization of approximately $2.08 billion. Market valuations fluctuate based on clinical updates regarding its proprietary TANGO platform and treatments for severe genetic diseases.